AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Combination Therapy Strategies for Hidradenitis Suppurativa

Description

The talk discusses combination therapy strategies for hidradenitis suppurativa (HS), emphasizing a need for diverse treatment options due to the limited number of FDA-approved therapies. With only two approved drugs, treatments typically combine older, established medications and antibiotics with biologics. The presentation outlines strategies for early-stage HS, focusing on the use of antibiotics, anti-inflammatories like isotretinoin and acetretin, and hormonal agents. It highlights the importance of targeting multiple aspects of HS pathogenesis, particularly in early intervention when lesions first appear. For late-stage HS, the discussion covers the use of TNF inhibitors like adalimumab and infliximab, IL-17 inhibitors such as secukinumab and bimikizumab, and the potential of Jack inhibitors, while noting the need for higher dosing for effectiveness. Combining these therapies may address the multifaceted nature of HS, allowing for consideration of various medications based on patient needs. The speaker advocates for using diverse therapeutic mechanisms to tackle one disease and presents anecdotal evidence for successful treatment combinations, including the role of GLP-1 inhibitors in patient care. Overall, the talk underscores the importance of personalized, multifaceted treatment approaches in managing HS.

View more

Conclusions

  • Combination therapies are essential for managing hidradenitis suppurativa (HS) due to the limited number of FDA approved treatments.
  • A variety of treatment combinations have been explored, often involving biologics and antibiotics.
  • Early intervention using combination therapies, particularly in the early stages of HS, can significantly impact patient outcomes.
  • Evidence suggests that combining biologics with symptomatic treatments can enhance efficacy and manage flare-ups.
  • Retinoids, anti-inflammatories, and hormonal therapies can be effectively paired with biologics for better outcomes in HS patients.
  • Monitoring is crucial when using combination therapies to manage potential side effects and effectiveness of the treatment.
  • The introduction of GLP-1 inhibitors in the treatment regime offers a promising avenue for weight management in HS patients, which may improve their overall condition.
  • Utilizing JAK inhibitors early and considering multi-modal targeting of the disease pathology may lead to better management of HS.
  • Patients benefit from individualized treatment strategies that encompass multiple mechanisms of action to address the complexities of HS.
  • Br J Dermatol 2024; 190:149-162
  • Sabat, R. Nature Reviews Disease Primers ., 6(1)
  • Bechara FG et al. JAMA Surg. 2021 Nov 1;156(11):1001-1009.
  • Kimball, A. et al. AAD Late-Breaking Research Program. New Orleans, LA March 17-21 2023
  • Tanya Henry, Brian Cahn, MD, Roger Haber, MD, John T. Landers, MD, Reed Berger-Fleishman, MD, Murad Alam, MD, and Sheryl Hoyer, MD. "Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa."
  • Dr Claire Drumm, Dr Julieanne Clowry, Prof Marie-Louise Healy, Dr Bairbre Wynne. "Successful Treatment of Hidradenitis Suppurativa with Semaglutide."